CRBP250117P20000
- 4.26
- 0.000.00%
Corbus Pharmaceuticals Newsroom
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Corbus Pharmaceuticals (CRBP) and Fortrea Holdings Inc. (FTRE)
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Promising Potential of Corbus Pharmaceuticals: Buy Rating Reinforced by Key Assets and Strategic Focus
Corbus Pharmaceuticals Analyst Ratings
Piper Sandler Initiates Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $35
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $65
Corbus Pharmaceuticals (CRBP) Receives a Buy From RBC Capital
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $60
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $75
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $80
Corbus Pharmaceuticals' CRB-913: A Promising and Safer Alternative in Obesity Treatment With a Buy Rating
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $60
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Corbus Pharmaceuticals (CRBP) Receives a Buy From Mizuho Securities
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $42 From $74, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Sonova Holding AG (Six Swiss: CH:SOON) and Corbus Pharmaceuticals (CRBP)
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $74
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $80